Telix Pharmaceuticals Limited (ASX:TLX) Insider Purchases A$343,384.37 in Stock

Telix Pharmaceuticals Limited (ASX:TLX – Get Rating) insider Tiffany Olson bought 51,305 shares of the firm’s stock in a transaction dated Thursday, March 16th. The stock was purchased at an average price of A$6.69 ($4.46) per share, for a total transaction of A$343,384.37 ($228,922.91).

Telix Pharmaceuticals Stock Performance

The company has a debt-to-equity ratio of 13.06, a current ratio of 2.03 and a quick ratio of 3.00.

Telix Pharmaceuticals Company Profile

(Get Rating)

Telix Pharmaceuticals Limited, a radiopharmaceutical company, develops molecularly targeted radiation (MTR) products for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. The company focuses on developing diagnostic and therapeutic products using MTR. Its lead products include TLX591-CDx for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX66-CDx to treat bone marrow conditioning and rare diseases; TLX250, which is in Phase II clinical trials for the diagnosis and treatment of renal (kidney) cancer; TLX250-CDx that is in Phase III clinical trials for the diagnosis and treatment of renal (kidney) cancer; TLX591, which is in Phase III clinical trials for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX101 that is in Phase I/II clinical trials and TLX101-CDx for the diagnosis and treatment of glioblastoma (brain cancer); and TLX66, which is in Phase I/IIa clinical trials for the treatment of bone marrow conditioning and rare diseases.